Achieve Life Sciences, Inc. (ACHV)
NASDAQ: ACHV · Real-Time Price · USD
6.02
+0.32 (5.61%)
At close: Jun 26, 2026, 4:00 PM EDT
5.94
-0.08 (-1.33%)
After-hours: Jun 26, 2026, 7:56 PM EDT
Company Description
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom.
The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms.
It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.
Achieve Life Sciences, Inc.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 28 |
| CEO | Andrew Goldberg |
Contact Details
Address: 22722 29th Dr. SE, Suite 100 Bothell, Washington 98021 United States | |
| Phone | 604 210 2217 |
| Website | achievelifesciences.com |
Stock Details
| Ticker Symbol | ACHV |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000949858 |
| CUSIP Number | 004468203 |
| ISIN Number | US0044685008 |
| Employer ID | 95-4343413 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Dr. Andrew D. Goldberg M.D. | Chief Executive Officer, President and Director |
| Erik Atkisson | Chief Legal Officer |
| Mark K. Oki CPA | Chief Financial Officer |
| Jerry Wan | Vice President of Finance and Principal Accounting Officer |
| Mark Zappia | Senior Vice President of Commercial |
| Nicole P. Jones | Vice President of Strategic Communications and Stakeholder Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 8, 2026 | ARS | Filing |
| Jun 8, 2026 | DEF 14A | Other definitive proxy statements |
| Jun 2, 2026 | 8-K | Current Report |
| May 29, 2026 | PRE 14A | Other preliminary proxy statements |
| May 21, 2026 | EFFECT | Notice of Effectiveness |
| May 12, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 12, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| May 12, 2026 | 10-Q | Quarterly Report |
| May 12, 2026 | 8-K | Current Report |
| May 7, 2026 | SCHEDULE 13G/A | Filing |